Dhampur Bio

Has Dhampur Bio declared dividend?

Yes, Dhampur Bio Organics Ltd has declared a 25% dividend, amounting to ₹2.5 per share, with an ex-date of June 28, 2024. However, the company has experienced significant price declines, resulting in total returns of -38.81% over the last 6 months and -34.19% over the past year.

Dhampur Bio Organics Ltd has declared a 25% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 25%<BR>- Amount per share: 2.5<BR>- Ex-date: Jun-28-2024<BR><BR>Dividend Yield: 3.29%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -38.81%, the dividend return was 0%, resulting in a total return of -38.81%.<BR><BR>Over the past year, the price return was -36.03%, with a dividend return of 1.84%, leading to a total return of -34.19%.<BR><BR>For the 2-year period, the price return was -50.95%, the dividend return was 3.35%, culminating in a total return of -47.6%.<BR><BR>In the 3-year timeframe, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 4 years, the price return was 0%, the dividend return was 0%, leading to a total return of 0.0%.<BR><BR>In the 5-year period, the price return was 0%, the dividend return was 0%, resulting in a total return of 0.0%.<BR><BR>Overall, while Dhampur Bio has declared a dividend, the total returns over various periods indicate significant declines in price, particularly over the last 6 months and 1 year, highlighting a challenging performance despite the dividend yield.

Who are the peers of the Dhampur Bio?

Dhampur Bio's peers include Dhampur Sugar, Avadh Sugar, Magadh Sugar, Dwarikesh Sugar, Zuari Industries, Ugar Sugar Works, KCP Sugar & Inds., Mawana Sugars, and Davangere Sugar. In terms of returns, Dhampur Bio has a 1-year return of -28.39%, better than Davangere Sugar's -57.94% and Dwarikesh Sugar's -36.15%.

Peers: The peers of Dhampur Bio are Dhampur Sugar, Avadh Sugar, Magadh Sugar, Dwarikesh Sugar, Zuari Industries, Ugar Sugar Works, KCP Sugar & Inds., Mawana Sugars, and Davangere Sugar.<BR><BR>Quality Snapshot: Excellent management risk is observed at Kothari Sugars, while Average management risk is found at Dhampur Sugar, Avadh Sugar, Magadh Sugar, Dwarikesh Sugar, Ugar Sugar Works, KCP Sugar & Inds., Mawana Sugars, and the rest. Below Average management risk is noted at Zuari Industries and Davangere Sugar. Growth is rated as Good at Mawana Sugars, Below Average at Dhampur Sugar, Avadh Sugar, Magadh Sugar, Ugar Sugar Works, and the rest, and Average at KCP Sugar & Inds. Capital Structure is Excellent at Kothari Sugars, Good at Dwarikesh Sugar, and Below Average at Dhampur Sugar, Avadh Sugar, Magadh Sugar, Zuari Industries, Dhampur Bio, Ugar Sugar Works, KCP Sugar & Inds., Mawana Sugars, and Davangere Sugar.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Davangere Sugar at -57.94%, while the lowest is Dwarikesh Sugar at -36.15%. Dhampur Bio's 1-year return is -28.39%, which is better than both. Additionally, Ugar Sugar Works, KCP Sugar & Inds., and Davangere Sugar have negative six-month returns.

Who are in the management team of Dhampur Bio?

As of March 2023, the management team of Dhampur Bio includes V K Goel (Executive Chairman), A K Gupta (Vice Chairman), Gautam Goel (Managing Director), and several independent directors, with total remuneration ranging from INR 14.9 lakh to INR 5.41 crore. They oversee the company's operations and strategic direction.

As of March 2023, the management team of Dhampur Bio includes the following individuals:<BR><BR>1. V K Goel - Executive Chairman (Remuneration: INR 3.48 crore)<BR>2. A K Gupta - Vice Chairman (Remuneration: INR 16.6 lakh)<BR>3. Gautam Goel - Managing Director (Remuneration: INR 5.41 crore)<BR>4. Sandeep Kumar Sharma - Whole-time Director (Remuneration: INR 1.42 crore)<BR>5. Bindu Vashist Goel - Director (Remuneration: INR 14.9 lakh)<BR>6. Ruchika Mehra Kothari - Independent Director (Remuneration: INR 14.9 lakh)<BR>7. Vishal Saluja - Independent Director (Remuneration: INR 15.4 lakh)<BR>8. Samir Thukral - Independent Director (Remuneration: INR 15.7 lakh)<BR>9. Kishor Shah - Independent Director (Remuneration: INR 15.7 lakh)<BR>10. Ashu Rawat - Company Secretary & Compliance Officer (Remuneration: INR 19.0 lakh)<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

What does Dhampur Bio do?

Dhampur Bio Organics Ltd, a micro-cap company in the sugar industry, was incorporated in 2020 and reported net sales of 4,643 Cr and a net profit of 448 Cr for March 2025. Key metrics include a P/E of 40.00, a dividend yield of 1.22%, and a market cap of INR 672 Cr.

Overview: <BR>Dhampur Bio Organics Ltd operates in the sugar industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was incorporated in 2020 as "RMSD Enterprises Private Limited" and later converted into a public limited company named "Dhampur Bio Organics Limited" in 2021. The most recent quarterly results reported net sales and profit for March 2025.<BR><BR>Financial Snapshot: <BR>Net Sales: 4,643 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: 448 Cr (Quarterly Results - Mar 2025) <BR>Market-cap: INR 672 Cr (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 40.00 <BR>Industry P/E: 25 <BR>Dividend Yield: 1.22% <BR>Debt Equity: 1.11 <BR>Return on Equity: 1.63% <BR>Price to Book: 0.64 <BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the top shareholders of the Dhampur Bio?

The top shareholders of Dhampur Bio include Sonitron Limited with 17.28%, individual investor Anil Kumar Goel at 9.04%, and individual investors collectively holding 40.43%. Additionally, 12 foreign institutional investors hold 0.54%, while mutual funds have no significant holdings.

The top shareholders of Dhampur Bio include the promoters, who hold the majority of the shares. The promoter with the highest holding is Sonitron Limited, which owns 17.28% of the company. In terms of public shareholders, Anil Kumar Goel is the largest individual investor, holding 9.04%. Additionally, individual investors collectively hold 40.43% of the shares. There are also 12 foreign institutional investors (FIIs) with a combined holding of 0.54%, and three mutual fund schemes that hold 0.0%.

How big is Dhampur Bio?

As of 24th July, Dhampur Bio Organics Ltd has a market capitalization of 631.00 Cr and reported net sales of 1861.54 Cr and a net profit of 14.69 Cr over the latest four quarters.

As of 24th July, <BR><BR>Market Cap: Dhampur Bio Organics Ltd has a market capitalization of 631.00 Cr, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: The sum of Net Sales for the latest 4 quarters is 1861.54 Cr, while the sum of Net Profit for the same period is 14.69 Cr.<BR><BR>Balance Sheet Snapshot: The reporting period is March 2025, with Shareholder's Funds amounting to 1,011.74 Cr and Total Assets valued at 2,397.53 Cr.

Is Dhampur Bio overvalued or undervalued?

As of October 10, 2025, Dhampur Bio is considered very attractive and undervalued, with a PE ratio of -95.86, a low price-to-book value of 0.54, and an EV to EBITDA ratio of 16.15, especially when compared to peers like EID Parry and Balrampur Chini, despite its year-to-date stock performance lagging at -28.53% against the Sensex's 5.58%.

As of 10 October 2025, the valuation grade for Dhampur Bio has moved from attractive to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, particularly when analyzing its key ratios. The PE ratio stands at -95.86, while the price-to-book value is a low 0.54, suggesting that the stock is trading well below its book value. Additionally, the EV to EBITDA ratio is 16.15, which, while higher than some peers, still reflects a favorable valuation in the context of the overall market.<BR><BR>In comparison to its peers, Dhampur Bio's valuation metrics stand out. EID Parry, categorized as very expensive, has a PE ratio of 23.46, while Balrampur Chini, rated fair, shows a PE of 23.07. This stark contrast highlights Dhampur Bio's undervaluation relative to its competitors. Furthermore, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -28.53% compared to the Sensex's 5.58%. This underperformance reinforces the notion that the stock may be undervalued, presenting a potential opportunity for investors.

When is the next results date for Dhampur Bio?

The next results date for Dhampur Bio is 13 November 2025.

The next results date for Dhampur Bio is scheduled for 13 November 2025.

How has been the historical performance of Dhampur Bio?

Dhampur Bio's historical performance shows a decline in net sales, operating profit, and profit after tax over the past four years, with significant drops from March 2023 to March 2025, despite an increase in total assets and liabilities. Cash flow from operating activities turned negative in March 2024, indicating a downward trend in profitability.

Answer:<BR>The historical performance of Dhampur Bio shows fluctuations in key financial metrics over the past four years.<BR><BR>Breakdown:<BR>Dhampur Bio's net sales for the year ending March 2025 were reported at 1,861.54 crore, slightly down from 1,864.44 crore in March 2024 and significantly lower than 2,407.53 crore in March 2023. The total operating income mirrored this trend, remaining almost flat from the previous year but showing a decline from the prior two years. The total expenditure, excluding depreciation, was 1,726.74 crore in March 2025, a minor decrease from 1,728.01 crore in March 2024, yet lower than 2,202.81 crore in March 2023. Operating profit (PBDIT) for March 2025 was 138.46 crore, down from 160.30 crore in March 2024 and 216.14 crore in March 2023. Profit before tax also saw a decline to 15.71 crore in March 2025 from 65.49 crore in March 2024 and 134.77 crore in March 2023. Consequently, profit after tax dropped to 14.69 crore in March 2025 from 46.49 crore in March 2024 and 111.10 crore in March 2023. The company's total assets increased to 2,397.53 crore in March 2025 from 2,312.81 crore in March 2024, while total liabilities also rose to 2,397.53 crore from 2,312.81 crore in the same period. Cash flow from operating activities turned negative at -101 crore in March 2024, contrasting with a positive cash flow of 368 crore in March 2023. Overall, the financial performance of Dhampur Bio indicates a downward trend in profitability and sales over the last few years, despite an increase in total assets and liabilities.

Is Dhampur Bio technically bullish or bearish?

As of December 2, 2025, Dhampur Bio's technical trend is neutral with mixed indicators, showing a mildly bearish weekly and monthly MACD, mildly bullish daily moving averages, and a lack of strong momentum overall.

As of 2 December 2025, the technical trend for Dhampur Bio has changed from mildly bearish to sideways. The current stance is neutral, with mixed indicators influencing the outlook. The weekly MACD remains bearish, while the monthly MACD is mildly bearish, indicating a lack of strong upward momentum. The Bollinger Bands also reflect a mildly bearish sentiment on both weekly and monthly time frames. However, the daily moving averages show a mildly bullish signal, suggesting some short-term strength. The Dow Theory indicates a mildly bullish stance on the weekly chart, but no trend is present on the monthly chart. Overall, the technical indicators present a conflicting picture, leading to a neutral stance with no strong bullish or bearish momentum.

Are Dhampur Bio Organics Ltd latest results good or bad?

Dhampur Bio Organics Ltd's latest results show a significant quarterly profit increase of 205.69%, but a concerning year-over-year decline of 346.36%. While there are signs of recovery, ongoing challenges in profitability and below-average returns suggest caution for investors.

Dhampur Bio Organics Ltd's latest results present a mixed picture. In Q3 FY26, the company reported a net profit of ₹16.90 crores, which is a significant improvement of 205.69% compared to the previous quarter. This indicates a positive turnaround in profitability after experiencing losses in earlier quarters. However, on a year-over-year basis, the net profit reflects a concerning decline of 346.36%.<BR><BR>Revenue for the same quarter was ₹486.34 crores, which shows a decline of 12.79% from the previous quarter but an increase of 4.74% compared to the same quarter last year. This revenue drop is typical for the sugar industry due to seasonal fluctuations.<BR><BR>While the operating margin improved to 8.77% from a negative figure in the previous quarter, the overall financial health of the company raises some concerns. The cumulative net loss for the nine months ending December 2025 was ₹21.09 crores, indicating ongoing challenges in maintaining consistent profitability.<BR><BR>Furthermore, the company's return on equity (ROE) and return on capital employed (ROCE) are significantly below industry standards, suggesting inefficiencies in capital utilization. The high reliance on non-operating income to achieve profit also casts doubt on the sustainability of these results.<BR><BR>In summary, while there are signs of recovery in the latest quarter, the overall financial performance remains under pressure, and the company faces significant challenges in the competitive sugar sector. Investors should weigh these factors carefully when assessing the company's outlook.

Should I buy, sell or hold Dhampur Bio Organics Ltd?

Why is Dhampur Bio Organics Ltd falling/rising?

As of 02-Feb, Dhampur Bio Organics Ltd's stock price is stable at 101.70, with a significant monthly rise of +27.00%, outperforming the Sensex. This positive momentum is driven by strong recent financial results, but concerns remain about the company's long-term growth and low investor confidence.

As of 02-Feb, Dhampur Bio Organics Ltd's stock price is currently stable at 101.70, showing no change (0.00%). However, the stock has experienced a significant rise over the past month, with a return of +27.00%, while the benchmark Sensex has fallen by -4.78% during the same period. This indicates that the stock is outperforming the market.<BR><BR>The positive momentum can be attributed to the company's recent financial performance, as it declared strong results for December 2025 after two consecutive quarters of negative results. Notably, the profit before tax (PBT) grew by 423.0% compared to the previous four-quarter average, and the profit after tax (PAT) surged by an astonishing 3853.2%. Additionally, the company's debtors turnover ratio reached a high of 53.67 times, suggesting efficient management of receivables.<BR><BR>Despite these positive indicators, there are concerns regarding the company's long-term fundamental strength, as it has shown a -22.40% compound annual growth rate (CAGR) in operating profits over the last five years. Furthermore, the average return on equity (ROE) stands at a low 4.07%, indicating limited profitability relative to shareholders' funds. The lack of investment from domestic mutual funds, which hold 0% of the company, may also reflect a lack of confidence in the stock's valuation or business prospects.<BR><BR>Overall, while the stock is currently stable, its recent rise can be attributed to strong quarterly results and outperformance against the benchmark, despite underlying concerns about long-term growth and investor participation.

Which are the latest news on Dhampur Bio?